NEW YORK, June 2, 2016 /PRNewswire/ --
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
Massachusetts headquartered biopharma Company, Genocea Biosciences Inc.'s stock finished Wednesday's trading session 0.64% higher at $4.73 with a total volume of 642,000 shares traded. The Company's shares have advanced 10.77% in the past month and 13.16% in the previous three months. The stock is trading below its 50-day moving average by 0.14%. Additionally, shares of Genocea Biosciences have a Relative Strength Index (RSI) of 55.62. Sign up and get the alert on GNCA at:
On Wednesday, shares in North Carolina headquartered specialty pharmaceutical Company, BioDelivery Sciences International Inc., ended the session at $2.20, which was a correction of 2.22%. The stock recorded a trading volume of 730,391 shares. The Company's shares are trading 25.21% below their 50-day moving average. Moreover, BioDelivery Sciences International's stock has an RSI of 37.53. The complimentary alert on BDSI can be activated at:
INSYS Therapeutics Inc.'s stock surged 7.28%, closing the session at $16.79. The Company develops and commercializes supportive care products. The stock recorded a trading volume of 881,569 shares, which was higher than its three months average volume of 709,960 shares. The Company's shares have gained 16.27% in the last one month. The stock is trading 10.33% above its 50-day moving average. Additionally, shares of INSYS Therapeutics have an RSI of 63.41. Register for free on ActiveWallSt.com and access the latest strategies on INSY at:
At the close on Wednesday, shares in Agios Pharmaceuticals Inc. recorded a trading volume of 834,929 shares, which was above their three months average volume of 700,150 shares. The Company engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the U.S. The stock ended the day 2.48% higher at $57.34. The Company's shares have advanced 15.28% in the past month and 30.91% over the previous three months. The stock is trading above its 50-day moving average by 22.49%. Furthermore, shares of Agios Pharmaceuticals have an RSI of 67.64. The complete trade setup on AGIO is available for free at:
Active Wall Street:
Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
AWS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly at: Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom Email: firstname.lastname@example.org Phone number: 1-858-257-3144 CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA